AbbVie (ABBV) announced that Emrelis has been granted accelerated approval by the U.S. Food and Drug Administration for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy. “This indication is approved based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Emrelis is a c-Met-directed antibody-drug conjugate and the first and only treatment approved for this patient population. ADCs are designed to target unique biomarkers such as the c-Met protein and deliver a potent ‘payload’ directly to the biomarker-expressing cell,” the company stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Biotech Alert: Searches spiking for these stocks today
- AbbVie and ADARx announce collaboration and license option agreement
- AbbVie downgraded to Neutral from Buy at Citi
- AbbVie Hold Rating: Balancing Growth in Immunology and Neuroscience Amidst Humira Challenges and Macroeconomic Uncertainties
- AbbVie Expands Board, Appoints New Independent Director
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue